Drugs / Resveratrol
Resveratrol
also known as
Trans-resveratrol · BIA 6-512 · RSV · 3,5,4-trihydroxystilbene · resVida · (Transmax) trans- resveratrol · 1,3-Benzenediol, 5-\[2-(4-hydroxyphenyl)ethenyl\]-, (E) · 3,5,4-trihydroxy-trans-stilbene · +5 more
Small molecule targets ESR1, NLRP3, SIRT1 via inhibition / activation
Trials 62 · started per year
today
3
3
4
2
4
2
3
3
2
4
5
2
5
2
2
5
2
1
3
2
3
2004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT04449198 | Oct 2020 → Jan 2027 expected | type 1 diabetes mellitus | Augusta University | Recruiting | No outcome recorded |
| Phase 0 | NCT04166396 | Feb 2020 → Jul 2024 | cystic fibrosis | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 0 | NCT02704494 | Mar 2016 → Feb 2017 | diabetic kidney disease | Shiraz University of Medical Sciences | Completed | Mixed |
| Phase 120 trials · 1 met primary | ||||||
| Phase 1 | NCT07397026 | Aug 2025 → Mar 2026 overdue | chronic periodontitis | Hagar Ahmed Ali Mohammed Elzain | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05736224 | May → Sep 2023 | skin cancer | Yale University | Completed | Met primary |
| Phase 1 | NCT04994561 | Jun 2022 → Dec 2023 | — | Vitality in Aging Research Group, Inc. | Withdrawn | No outcome recorded |
| Phase 1 | NCT04668274 | Jan → Feb 2021 | — | Jupiter Orphan Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04421079 | Jan 2021 → Dec 2024 | — | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 1 | NCT02502253 | Jun 2015 → Jun 2022 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT01370889 | Jun 2011 → Jul 2012 | — | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01126229 | Nov 2009 → Dec 2012 | — | University of Florida | Completed | No outcome recorded |
| Phase 1 | NCT01677611 | Dec 2008 → Sep 2010 | type 2 diabetes mellitus | Khoo Teck Puat Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00721877 | Aug 2008 → Jul 2009 | — | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00433576 | Dec 2006 → Nov 2008 | colon adenocarcinoma, rectum adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT03097211 | Jul → Oct 2006 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT03094156 | Apr → Jul 2006 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT03095105 | Jan → Mar 2006 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT00256334 | Jul 2005 → Dec 2008 | colon carcinoma | University of California, Irvine | Completed | No outcome recorded |
| Phase 1 | NCT03095092 | May → Jul 2005 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT03093389 | May → Jul 2005 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT03091868 | Nov 2004 → Feb 2005 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT00098969 | Sep 2004 → ? | cancer of unknown primary site | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT03091543 | May → Jul 2004 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01842399 | Jul 2015 → Jul 2020 | hypertensive disorder | National Institute on Aging (NIA) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT01321151 | Mar → Nov 2011 | — | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 217 trials · 1 missed | ||||||
| Phase 2 | NCT07592767 | Sep 2026 → Jun 2028 expected | Parkinson disease | Georgetown University | Recruiting | No outcome recorded |
| Phase 2 | NCT07100613 | Sep 2024 → Oct 2027 expected | lichen planus, oral, mouth mucosa disorder | University of Palermo | Recruiting | No outcome recorded |
| Phase 2 | NCT06470061 | Jul 2024 → Jul 2027 expected | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Zaparackas and Knepper LTD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05062486 | Oct 2021 → Nov 2024 | age-related macular degeneration | Paul A Knepper, MD PhD | Completed | No outcome recorded |
| Phase 2 | NCT03866200 | Jun 2019 → Oct 2020 | pseudoachondroplasia | The University of Texas Health Science Center, Houston | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03933163 | May 2019 → Mar 2024 | Friedreich ataxia | Murdoch Childrens Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT03665740 | Aug 2018 → Aug 2022 | persian gulf syndrome | VISN 17 Center of Excellence | Unknown | No outcome recorded |
| Phase 2 | NCT03253913 | Mar 2018 → Oct 2022 | lymphangioleiomyomatosis | University of Cincinnati | Completed | Missed primary |
| Phase 2 | NCT03525379 | Oct 2017 → Oct 2019 | congestive heart failure | University of Alberta | Completed | No outcome recorded |
| Phase 2 | NCT02549924 | Sep 2016 → Jan 2018 | type 2 diabetes mellitus | University of Guadalajara | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02523274 | Jun 2016 → May 2019 | — | University of Florida | Completed | No outcome recorded |
| Phase 2 | NCT01504854 | May 2012 → Mar 2014 | Alzheimer disease | Alzheimer's Disease Cooperative Study (ADCS) | Completed | No outcome recorded |
| Phase 2 | NCT02114892 | Apr 2012 → Jul 2013 | metabolic syndrome X | University of Guadalajara | Completed | No outcome recorded |
| Phase 2 | NCT02247596 | Jul 2009 → Oct 2012 | diabetes mellitus, obesity disorder | Khoo Teck Puat Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01354977 | Mar 2008 → Sep 2017 | type 2 diabetes mellitus | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT00654667 | May 2007 → Aug 2008 | — | University of California, San Francisco | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00455416 | Apr 2007 → Apr 2009 | follicular lymphoma | Oslo University Hospital | Unknown | No outcome recorded |
| Phase 35 trials · 1 missed | ||||||
| Phase 3 | NCT06882564 | Jan → Apr 2025 overdue | chronic gingivitis | Al-Mustansiriyah University | Recruiting | No outcome recorded |
| Phase 3 | NCT04886297 | May 2021 → May 2022 | hyperlipidemia | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT03446625 | Mar → Oct 2018 | infertility disorder | IVI Madrid | Completed | No outcome recorded |
| Phase 3 | NCT02905799 | Nov 2017 → Feb 2022 | osteoarthritis, knee | Assistance Publique - Hôpitaux de Paris | Completed | Missed primary |
| Phase 3 | NCT03683108 | Dec 2015 → Mar 2018 | common cold | Policlinico Hospital | Completed | No outcome recorded |
| Phase 45 trials · 1 missed | ||||||
| Phase 4 | NCT07868458 | Sep 2026 | diabetic retinopathy | University of Athens | Completed | No outcome recorded |
| Phase 4 | NCT03384329 | Jul 2018 → Aug 2019 | depressive disorder | Russian Academy of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT03349619 | Mar → Jul 2018 | allergic rhinitis | Istituto per la Ricerca e l'Innovazione Biomedica | Completed | No outcome recorded |
| Phase 4 | NCT02947932 | Dec 2016 → Mar 2018 | acute pancreatitis | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 4 | NCT02475564 | Jun → Nov 2015 | endometriosis | Hospital de Clinicas de Porto Alegre | Completed | Missed primary |
| Phase not applicable10 trials | ||||||
| — | NCT07569744 | May → Jun 2026 | type 2 diabetes mellitus | Universitas Sriwijaya | Completed | No outcome recorded |
| — | NCT06521333 | May 2024 → Dec 2025 | gingival recession | Cairo University | Completed | No outcome recorded |
| — | NCT05410093 | Feb 2022 → Jul 2024 | primary ovarian failure | Affiliated Hospital of Nantong University | Unknown | No outcome recorded |
| — | NCT04799743 | Apr 2021 → May 2022 | COVID-19 | Hong Kong Baptist University | Unknown | No outcome recorded |
| — | NCT03546530 | Jun 2016 → Jan 2017 | chronic hepatitis B virus infection | The First Hospital of Jilin University | Completed | No outcome recorded |
| — | NCT03509688 | Nov 2014 → Dec 2017 | hepatitis | The First Hospital of Jilin University | Completed | No outcome recorded |
| — | NCT02321176 | Mar 2014 → Apr 2015 | eye disorder | Huazhong University of Science and Technology | Unknown | No outcome recorded |
| — | NCT01668836 | Aug 2012 → Jul 2014 | — | InCor Heart Institute | Completed | No outcome recorded |
| — | NCT01375959 | Apr 2011 → Apr 2014 | glucose intolerance | Albert Einstein College of Medicine | Completed | No outcome recorded |
| — | NCT01158417 | Dec 2008 → Jul 2012 | obesity disorder, type 2 diabetes mellitus | University at Buffalo | Terminated | No outcome recorded |
| Comparator or background therapy16 trials | ||||||
| Phase 0 | NCT03819517 Comparator | Jul 2019 → Aug 2022 | chronic obstructive pulmonary disease | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 1/2 | NCT01339884 Comparator | Apr 2011 → Aug 2012 | Friedreich ataxia | Murdoch Childrens Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT06131918 Comparator | Jan → Dec 2023 | diabetic polyneuropathy | Khyber Medical University Peshawar | Completed | No outcome recorded |
| Phase 2 | NCT04867252 Comparator | May → Aug 2021 | polycystic ovary syndrome | Khyber Medical University Peshawar | Completed | No outcome recorded |
| Phase 2 | NCT04400890 Comparator | Sep 2020 → Mar 2021 | COVID-19 | Marvin McCreary, MD | Terminated | No outcome recorded |
| Phase 2 | NCT02123121 Comparator | Sep 2015 → May 2019 | — | University of Florida | Completed | No outcome recorded |
| Phase 2 | NCT02062190 Comparator | Mar 2014 → Jan 2015 | schizophrenia | Federal University of Rio Grande do Sul | Completed | No outcome recorded |
| Phase 2 | NCT01451918 Comparator | Oct 2011 → Sep 2013 | hyperlipidemia | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2 | NCT01615445 Comparator | Feb 2009 → Aug 2011 | — | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT03743636 Comparator | Oct 2018 → May 2023 | peripheral arterial disease | Northwestern University | Completed | No outcome recorded |
| Phase 3 | NCT02130440 Comparator | Nov 2012 → Dec 2013 | seasonal allergic rhinitis | University of Campania Luigi Vanvitelli | Completed | No outcome recorded |
| Phase 4 | NCT02766803 Comparator | May 2016 → Jun 2017 | polycystic ovary syndrome | Poznan University of Medical Sciences | Unknown | No outcome recorded |
| — | NCT07060157 Comparator | Jul 2025 → Aug 2026 overdue | hyperpigmentation of the skin | Assiut University | Not yet recruiting | No outcome recorded |
| — | NCT05172947 Comparator | Dec 2021 → Dec 2022 | diabetic neuropathy | University of Sulaimani | Completed | No outcome recorded |
| — | NCT02246660 Comparator | Jan 2015 → Jul 2016 | peripheral arterial disease | Northwestern University | Completed | No outcome recorded |
| — | NCT01766180 Comparator | Jan 2013 → Jan 2016 | amnestic disorder | Neurolgy Institute for Brain Health and Fitness | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2025-11-05 | Jupiter Neuroscience Inc. | Regulatory Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson's Disease jupiterneurosciences.com ↗ |
| 2025-07-23 | Jupiter Neuroscience Inc. | Results Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science jupiterneurosciences.com ↗
In a Phase I clinical trial, JOTROL ™ achieved a nine-fold increase in bioavailability compared to traditional resveratrol, without the GI toxicity seen at high doses. |
| 2023-02-27 | Jupiter Neuroscience Inc. | Results Jupiter Neurosciences, Inc. Announces Research Breakthrough with JOTROL™ in Parkinson's Disease jupiterneurosciences.com ↗
Additional findings include JOTROL™ significantly improving an outcome used to evaluate motor coordination, rotarod performance; significantly improving behavioral characteristics induced in the animal model; as well as being generally safe and well tolerated. |
| 2022-06-14 | Jupiter Neuroscience Inc. | Results Jupiter Neurosciences, Inc. Announces Journal of Alzheimer's Disease Publication Highlighting use of JOTROL™ jupiterneurosciences.com ↗
The results showed that JOTROL™ significantly increased bioavailability over non-formulated resveratrol and that treatment resulted in AD-related gene expression changes, as well as changes in inflammatory gene and cytokine levels. |
| 2022-02-23 | Jupiter Neuroscience Inc. | Results Jupiter Neurosciences, Inc. Announces Completion of Phase I Safety Trial with Enhanced Resveratrol Product, JOTROL™ jupiterneurosciences.com ↗
JOTROL™ was determined to be safe and well tolerated at all dose levels administered, with the data safety monitoring board (DSMB) reporting no serious adverse events (SAEs). |
All press releases naming this drug 8 releases
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 82 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Resveratrol | “Resveratrol (RSV) - or Trans-resveratrol- is polyphenolic compound in many plants, including grape, peanut, and berries.” NCT07592767 ↗64“resveratrol 500 mg capsules, 3 capsules (1500 mg) orally twice a day for 6 weeks” NCT01375959 ↗ “Resveratrol is a compound found in the skin of red grapes.” NCT01842399 ↗ |
| Known as | (Transmax) trans- resveratrol | “Resveratrol- (Transmax) trans- resveratrol (Biotivia Longevity Bioceuticals, LLC, New York, USA) in cellulose capsules.” NCT03525379 ↗ |
| Known as | 1,3-Benzenediol, 5-\[2-(4-hydroxyphenyl)ethenyl\]-, (E) | “Drug name: Micronised resveratrol. Dosage form: 500mg capsules. Alternate name: 1,3-Benzenediol, 5-\[2-(4-hydroxyphenyl)ethenyl\]-, (E). Ingredients: 99.50% pure trans-resveratrol.” NCT03933163 ↗ |
| Known as | 3,5,4-trihydroxy-trans-stilbene | “Resveratrol (3,5,4-trihydroxy-trans-stilbene) belongs to polyphenols stilbene group found in grapes, peanuts, red wine and many medicinal plants.” NCT04867252 ↗ |
| Known as | 3,5,4-trihydroxystilbene | “For example, resveratrol (3,5,4'-trihydroxystilbene) which is a polyphenol compound that is commonly found in grapes, is a nutritional supplement with anti-oxidant and...” NCT01321151 ↗2“Resveratrol (3, 5, 4'-trihydroxystilbene) is a natural polyphenolic compound belongs to the large group of polyphenols found in different plant species.” NCT02704494 ↗ “Resveratrol (3,5,4-trihydroxystilbene) is a natural polyphenol with antioxidant, anti-inflammatory, and endothelial-protective effects.” NCT07569744 ↗ |
| Known as | BIA 6-512 | “The purpose of the study was to investigate the effect of food on the pharmacokinetics of a single 400 mg dose of BIA 6-512 (trans-resveratrol) in healthy volunteers” NCT03095092 ↗ |
| Known as | JOTROL | “Test Product: JOTROL (resveratrol) 100 mg resveratrol in 1000 mg softgel capsule for oral administration” NCT04668274 ↗ |
| Known as | JOTROLTM | “JOTROLTM is a micellar 10% resveratrol solubilization formulation that is thought to increase bioavailability of resveratrol via lymphatic system absorption.” PMID 35789594 ↗ Jun 2022 |
| Known as | Mega Resveratrol | “Mega Resveratrol” NCT02247596 ↗ |
| Known as | Micronised resveratrol | “Drug name: Micronised resveratrol. Dosage form: 500mg capsules. Alternate name: 1,3-Benzenediol, 5-\[2-(4-hydroxyphenyl)ethenyl\]-, (E). Ingredients: 99.50% pure trans-resveratrol.” NCT03933163 ↗ |
| Known as | resVida | “We will perform a 12-month trial of resVida (an oral preparation of resveratrol) in 120 randomized overweight/obese people over the age of 50 (40 in each group).” NCT01842399 ↗ |
| Known as | RSV | “Dietary resveratrol (RSV), a class of flavonoid compounds, have been demonstrated to exert several beneficial effects on human body.” PMID 30856465 ↗ Feb 20193“Resveratrol (RSV) - or Trans-resveratrol- is polyphenolic compound in many plants, including grape, peanut, and berries.” NCT07592767 ↗ “Resveratrol (RSV), a polyphenol found in red wine, has been shown in vitro to enhance SIRT1 activity.” NCT00654667 ↗ “Resveratrol (RSV) mouthwash was used by the test group” PMID 41328922 ↗ Dec 2025 |
| Known as | Trans-resveratrol | “The sunscreen contains bioadhesive nanoparticles (BNP) encapsulating avobenzone and octocrylene plus the non-toxic natural products diosmin, ferulic acid, cytisine and...” NCT05736224 ↗8“subjects will start taking daily nutritional supplements of 1,500 mg glucosamine, 600 mg nicotinamide riboside and 500 mg trans-resveratrol” NCT04994561 ↗ “The Effect of Food on the Pharmacokinetics of a Single 400 mg Oral Dose of BIA 6-512 (Trans-resveratrol) in Healthy Subjects” NCT03095092 ↗ “BIA 6-512 (Trans-resveratrol) in healthy volunteers” NCT03093389 ↗ “Four Single-doses of BIA 6-512 (Trans-resveratrol)” NCT03091543 ↗ “Dietary Supplement: Trans-resveratrol” NCT04421079 ↗ |
| Known as | Transmax | “Subjects will receive resveratrol (Transmax 1 x 500mg tablets bid for one week followed by 2 x 500mg bid for the second week (Biotivia Longevity Biologicals, New York, NY, USA)...” NCT01451918 ↗ |
| Action | Inhibit | “It has been shown to downregulate the levels of insulin-like growth factor-1 (IGF-I) in rodents.” PMID 20935227 ↗ Oct 2010 |
| Modality | Small molecule | “Resveratrol, a naturally occurring polyphenol, has cancer chemopreventive properties in preclinical models.” PMID 20935227 ↗ Oct 2010 |
| Route | Oral | “Participants receive oral resveratrol once on day 1.” NCT00098969 ↗ |
| Target | SIRT1 | “enhance SIRT1 activity” NCT00654667 ↗ |